Cell And Gene Therapy Market Size And Share

• In September 2023, Agilent Technologies Inc. signed a Memorandum of Understanding (MOU) with the Advanced Cell Therapy and Research Institute, Singapore (ACTRIS). This agreement aims to improve cell and gene therapy advancements over the next three years.
• In March 2022, Cellevolve Bio partnered with Seattle Children’s Therapeutics to develop and commercialize new multiplex CARs for pediatric cancers. With this collaboration, the companies will focus on the BrainChild research program—a suite of five multiplex CARs—to treat pediatric central nervous system (CNS) malignancies. They aim to leverage the Seattle Children’s Cure Factory facility to conduct early clinical GMP research on new CARs.

1. サーモフィッシャーサイエンティフィック社;
2. メルクKGaA;
3. チャールズリバーラボラトリーズ;
4. 細胞および遺伝子治療カタパルト;
5. ロンザ;
6. 無錫AppTec;